Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. (Q41143951)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8846622%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

review article

1 reference

title

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8846622%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

author name string

D A Flockhart

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8846622%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

publication date

1 January 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8846622%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

20 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8846622%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

volume

29 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8846622%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

page(s)

45-52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8846622%20AND%20SRC:MED&resulttype=core&format=json

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

20 October 2019

cites work

1 reference

12 December 2020

The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine

1 reference

12 December 2020

Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism

1 reference

12 December 2020

Debrisoquine and mephenytoin oxidation in Sinhalese: a population study

1 reference

12 December 2020

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

1 reference

12 December 2020

S-mephenytoin hydroxylation phenotypes in a Jordanian population

1 reference

12 December 2020

Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.

1 reference

12 December 2020

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism

1 reference

12 December 2020

Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population

1 reference

12 December 2020

Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

1 reference

12 December 2020

A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio

1 reference

12 December 2020

Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

1 reference

12 December 2020

Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography

1 reference

12 December 2020

S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin

1 reference

12 December 2020

Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

1 reference

12 December 2020

Phenotyping polymorphic drug metabolism in the French Caucasian population

1 reference

12 December 2020

1 reference

12 December 2020

Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland

1 reference

12 December 2020

Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities

1 reference

12 December 2020

The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study

1 reference

12 December 2020

Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism

1 reference

12 December 2020

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

1 reference

12 December 2020

Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects

1 reference

12 December 2020

Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man

1 reference

12 December 2020

Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test

1 reference

12 December 2020

Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes

1 reference

12 December 2020

Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner.

1 reference

12 December 2020

S-mephenytoin 4-hydroxylation in older Americans

1 reference

12 December 2020

Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver

1 reference

12 December 2020

Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers.

1 reference

12 December 2020

Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians

1 reference

12 December 2020

Non-competitive inhibition of clomipramine N-demethylation by fluvoxamine

1 reference

12 December 2020

Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians

1 reference

12 December 2020

Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism

1 reference

12 December 2020

Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man

1 reference

12 December 2020

Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies

1 reference

12 December 2020

Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation

1 reference

12 December 2020

Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark

1 reference

12 December 2020

Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients

1 reference

12 December 2020

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

1 reference

12 December 2020

Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms

1 reference

12 December 2020

Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital

1 reference

12 December 2020

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese

1 reference

12 December 2020

Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome

1 reference

12 December 2020

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans

1 reference

12 December 2020